Literature DB >> 16204716

Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas.

Ching-Yee Oliver Wong1, Joseph Thie, Kelly J Parling-Lynch, Dana Zakalik, Jeffrey H Margolis, Marianne Gaskill, Jack Hill, Feng Qing, Darlene Fink-Bennett, Conrad Nagle.   

Abstract

UNLABELLED: Our objective was to derive the best glucose sensitivity factor (g-value) and the most discriminating standardized uptake value (SUV) normalized to glucose for classifying indolent and aggressive lymphomas.
METHODS: The maximum SUV obtained from (18)F-FDG PET over the area of biopsy in 102 patients was normalized by serum glucose ([Glc]) to a standard of 100 mg/dL. Discriminant analysis was performed by using each SUV(100) (SUV x {100/[Glc]}(g), calculated using various g-values ranging from -3.0 to 0, one at a time) as a variable against the lymphoma grades, and plotting the percentage of correct classifications against g (g-plot) to search for the best g-value in normalizing SUV(100) for classifying grades. To address the influence of the extreme glucose conditions, we repeated the same analyses in 12 patients with [Glc] < or = 70 mg/dL or [Glc] > or = 110 mg/dL.
RESULTS: SUV(100) correctly classified lymphoma grades ranging from 62% to 73% (P < 0.0005), depending on the g-value, with a maximum at a g-value of -0.5. For the subgroup with extreme glucose values, the g-plot also revealed higher and more optimal discrimination at a g-value of -0.5 (92%) than at a g-value of 0 (83%) (P = 0.03). The discrimination deteriorated at g < -1 in both analyses. The box plot for all cases using a g-value of -0.5 showed little overlap in classifying lymphoma grades. For a visually selected threshold SUV(100) of 7.25, the sensitivity, specificity, and accuracy of identifying aggressive grades were 82%, 79%, and 81%, respectively.
CONCLUSION: The results suggest that metabolic discrimination between lymphoma grades using a glucose-normalized SUV from (18)F-FDG PET is improved by introducing g-value as an extra degree of freedom.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204716

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Role of Kinetic Modeling in Biomedical Imaging.

Authors:  Sung-Cheng Huang
Journal:  J Med Sci       Date:  2008

2.  Investigating the existence of quantum metabolic values in non-Hodgkin's lymphoma by 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography.

Authors:  Ching-yee Oliver Wong; Joseph Thie; Kelly J Parling-Lynch; Dana Zakalik; Regina H Wong; Marianne Gaskill; Jeffrey H Margolis; Jack Hill; Ammar Sukari; Surya Chundru; Darlene Fink-Bennett; Conrad Nagle
Journal:  Mol Imaging Biol       Date:  2007 Jan-Feb       Impact factor: 3.488

3.  Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?

Authors:  L Tessonnier; F Sebag; F F Palazzo; C Colavolpe; C De Micco; J Mancini; B Conte-Devolx; J F Henry; O Mundler; D Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

4.  Time sensitivity: a parameter reflecting tumor metabolic kinetics by variable dual-time F-18 FDG PET imaging.

Authors:  Ching-yee Oliver Wong; Daniel Noujaim; Hungsen F Fu; Wen-sheng Huang; Cheng-yi S Cheng; Joseph Thie; Ishani Dalal; Chih-yung Chang; Conrad Nagle
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

5.  Correlating metabolic activity with cellular proliferation in follicular lymphomas.

Authors:  Bingfeng Tang; Jozef Malysz; Vonda Douglas-Nikitin; Richard Zekman; Regina Heather Wong; Ishmael Jaiyesimi; Ching-Yee Oliver Wong
Journal:  Mol Imaging Biol       Date:  2009-05-09       Impact factor: 3.488

6.  Glucose corrected standardized uptake value (SUVgluc) in the evaluation of brain lesions with 18F-FDG PET.

Authors:  Asae Nozawa; Ali Hosseini Rivandi; Santosh Kesari; Carl K Hoh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-10       Impact factor: 9.236

7.  Quantitation of glucose uptake in tumors by dynamic FDG-PET has less glucose bias and lower variability when adjusted for partial saturation of glucose transport.

Authors:  Simon-Peter Williams; Judith E Flores-Mercado; Ruediger E Port; Thomas Bengtsson
Journal:  EJNMMI Res       Date:  2012-02-01       Impact factor: 3.138

8.  Factors affecting tumor (18) F-FDG uptake in longitudinal mouse PET studies.

Authors:  Wei Sha; Hu Ye; Keisuke S Iwamoto; Koon-Pong Wong; Moses Quinn Wilks; David Stout; William McBride; Sung-Cheng Huang
Journal:  EJNMMI Res       Date:  2013-07-10       Impact factor: 3.138

9.  Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer.

Authors:  Cecilia Marini; Barbara Salani; Michela Massollo; Adriana Amaro; Alessia Isabella Esposito; Anna Maria Orengo; Selene Capitanio; Laura Emionite; Mattia Riondato; Gianluca Bottoni; Cinzia Massara; Simona Boccardo; Marina Fabbi; Cristina Campi; Silvia Ravera; Giovanna Angelini; Silvia Morbelli; Michele Cilli; Renzo Cordera; Mauro Truini; Davide Maggi; Ulrich Pfeffer; Gianmario Sambuceti
Journal:  Cell Cycle       Date:  2013-11-15       Impact factor: 4.534

10.  Implications of Ambient Glucose Variation on the Target-to-Background Ratio of Hepatic Tumors By (18)FDG-PET Imaging.

Authors:  Prashant Jolepalem; Lesley Flynt; John N Rydberg; Ching-Yee Oliver Wong
Journal:  J Clin Imaging Sci       Date:  2014-07-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.